What is the incidence of confined placental mosaicism (CPM) for trisomy 21?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Incidence of Confined Placental Mosaicism for Trisomy 21

The incidence of confined placental mosaicism (CPM) for trisomy 21 is approximately 46% of cases where trisomy 21 mosaicism is detected in chorionic villus sampling (CVS). 1

Understanding Confined Placental Mosaicism

Confined placental mosaicism is characterized by the presence of chromosomally distinct cell lines that are limited to the placenta and not present in the fetus. This phenomenon occurs in approximately 2% of viable pregnancies studied by chorionic villus sampling at 9-11 weeks of gestation 2.

Key characteristics of CPM:

  • Represents tissue-specific chromosomal mosaicism affecting only the placenta
  • Diagnosed when chromosomal mosaicism is detected in CVS but subsequent amniocentesis shows a normal karyotype
  • Can involve various chromosomes with significantly different outcomes depending on which chromosome is affected

Trisomy 21 CPM: Incidence and Significance

According to the most recent comprehensive data from a Danish study examining 528 cases of autosomal trisomy mosaicism detected in CVS:

  • Among 41 cases of trisomy 21 mosaicism detected in CVS, 46% (19/41) showed fetal involvement 1
  • This means that 54% of trisomy 21 mosaicism cases detected in CVS represent confined placental mosaicism
  • This is significantly higher than many other chromosomes (e.g., trisomy 7 has 0% fetal involvement) 1

Clinical Implications and Risk Factors

The level of mosaicism in CVS samples appears to be clinically significant:

  • Higher levels of mosaicism suggest increased likelihood of fetal involvement
  • Mean mosaic level was 55% in true fetal mosaics vs. 28% in cases confined to the placenta 1

In cases of CPM (regardless of chromosome involved):

  • 14% risk of delivering small-for-gestational-age neonates
  • 15% risk of preterm birth (before 37 weeks)
  • 22% collective risk of adverse pregnancy outcomes 1

Detection and Monitoring

Modern screening methods have improved detection of CPM:

  • Introduction of combined first-trimester screening increased detection of placental mosaicism with fetal involvement
  • The risk of detecting fetal involvement increased from 9% before 2004 to 15% after 2004 1
  • Multiple-of-the-median (MoM) values of pregnancy-associated plasma protein A can be predictive of adverse outcomes 1

Mosaic Ratio and Pregnancy Outcomes

Recent research indicates:

  • A significantly higher mosaic ratio is found in cases with adverse pregnancy outcomes compared to those with normal outcomes
  • However, no clear threshold value can be established to predict outcomes, except potentially for trisomy 16 3

Clinical Considerations

When trisomy 21 mosaicism is detected in CVS:

  • Follow-up amniocentesis is essential to differentiate between generalized mosaicism and CPM
  • Fluorescent in situ hybridization (FISH) on uncultured amniotic fluid cells can help make this distinction 4
  • Detailed ultrasound monitoring is warranted even in confirmed CPM cases due to increased risk of adverse pregnancy outcomes

Unlike some other trisomies (such as trisomy 7), trisomy 21 CPM appears to have a higher rate of fetal involvement, making careful follow-up particularly important in these cases 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.